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BACKGROUND: Concurrent chemoradiotherapy is a valuable treatment option for localised oesophageal cancer (EC), but improvement
is still needed. A randomised phase II trial was initiated to assess the feasibility and efficacy in terms of the endoscopic complete
response rate (ECRR) of radiotherapy with oxaliplatin, leucovorin and fluorouracil (FOLFOX4) or cisplatin/fluorouracil.
METHODS: Patients with unresectable EC (any T, any N, M0 or M1a), or medically unfit for surgery, were randomly assigned to receive
either six cycles (three concomitant and three post-radiotherapy) of FOLFOX4 (arm A) or four cycles (two concomitant and two
post-radiotherapy) of cisplatin/fluorouracil (arm B) along with radiotherapy 50Gy in both arms. Responses were reviewed by
independent experts.
RESULTS: A total of 97 patients were randomised (arm A/B, 53/44) and 95 were assessable. The majority had squamous cell carcinoma
(82%; arm A/B, 42/38). Chemoradiotherapy was completed in 74 and 66%. The ECRR was 45 and 29% in arms A and B, respectively.
Median times to progression were 15.2 and 9.2 months and the median overall survival was 22.7 and 15.1 months in arms A and B,
respectively.
CONCLUSION: Chemoradiotherapy with FOLFOX4, a well-tolerated and convenient combination with promising efficacy, is now being
tested in a phase III trial.
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Although significant advances in the staging and treatment of
patients with oesophageal cancer (EC) have recently been seen,
this malignancy is still lethal for the majority of patients (American
Cancer Society, 2008). Chemoradiation was established as one of
the viable options for therapy of patients with localised EC
following the results from the landmark trial of the Radiation
Therapy Oncology Group (RTOG) 85-01 trial, showing a sig-
nificant survival advantage of concurrent chemoradiation over
radiation alone (Al-Sarraf et al, 1997; Cooper et al, 1999).
However, the local failure rate was 45% in the chemoradiation
arm (Al-Sarraf et al, 1997). It is worth to note that a majority of
squamous cell carcinomas (80%) were included in the RTOG
85-01. Moreover, the small cohort of adenocarcinomas treated with
chemoradiation achieved a lower 5-year survival rate as compared
with squamous cell (13 vs 21%) (Cooper et al, 1999). In addition,
20% of patients who received chemoradiation experienced life-
threatening side effects, and chemotherapy could not be completed
in 440% of the patients (Al-Sarraf et al, 1997). Therefore, safer
and more effective non-operative treatments are expected.
The FOLFOX4 regimen is a combination of oxaliplatin, fluoro-
uracil and leucovorin, which has demonstrated efficacy and
good tolerability in colorectal cancer (De Gramont et al, 2000;
Andre ´ et al, 2004). A similar regimen showed a good response rate
(40%) and a 1-year survival rate of 31% in advanced EC (Mauer
et al, 2005). In 2004, we performed a phase I trial to assess the
dose-limiting toxicity of the combination of radiotherapy with
oxaliplatin, fluorouracil and leucovorin every 2 weeks (Conroy
et al, 2008). The recommended doses for phase II studies of
fluorouracil and oxaliplatin with concurrent radiation were those
of the FOLFOX4 regimen (detailed below). Afterwards, we started
a randomised phase II–III study comparing our experimental
chemoradiation regimen with FOLFOX4 to the standard cisplatin/
fluorouracil chemoradiation combination in patients with EC.
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Design
This was a multicentre, randomised, open-label, phase II study to
test the feasibility (completion of full treatment) of the FOLFOX4
regimen vs the cisplatin/fluorouracil regimen in EC patients.
Patients were stratified for study centre and histological type.
The primary end points were the completion of full treatment
and endoscopic complete response rate (ECRR). Treatments
were considered as fully completed if patients received full doses
of radiotherapy and all cycles of chemotherapy (six cycles of
FOLFOX4 or four cycles of cisplatin/fluorouracil). An independent
data monitoring committee (IDMC) was set up to review the
ECRR, safety and other issues related to the conduct of the study.
The study was conducted in accordance with the Declaration of
Helsinki, Good Clinical Practice guidelines, and legal require-
ments. The protocol was approved by the Ethical Committee of
Lorraine. Written informed consent was obtained from all patients.
Three conditions needed to be fulfilled before initiating the
phase III part of the study: fast accrual rate (88 patients within
18 months), completion of full treatment in 460% of patients in
the experimental arm, and ECRR of FOLFOX4 equal or superior to
ECRR of cisplatin/fluorouracil.
Patient eligibility
Patients had to have histologically proven adenocarcinoma or
squamous cell or adenosquamous EC (any T, N0 or N1, M0 or
M1a) and previously untreated. Patients with technically unresect-
able cancer or those with surgical contraindications and those who
refused to undergo surgery were eligible. Additional inclusion
criteria were age X18 years, Eastern Cooperative Oncology Group
(ECOG) Performance Status (PS) p2, peripheral neuropathy
pNCI-CTC grade 1, sufficient caloric intake, life expectancy X3
months, and adequate bone marrow reserve, normal renal and
liver functions. Non-inclusion criteria were multiple ECs, weight
loss 420% normal body weight, previous radiotherapy, invasion
of the tracheo-bronchial tree, previous myocardial infarction,
symptomatic arteritis and other serious illness or medical
conditions.
Patients were randomised in a 1:1 ratio. A central stratified
block randomisation procedure was used to balance prognostic
factors between treatment arms and to minimise the predictability
of treatment allocation in this open label study. Investigator centre
and histology type were used as strata.
Each centre was attributed a fixed number of blocks, which were
allocated according to histology type. The SAS function ‘RANUNI’
with an arbitrary ‘SEED’ value was used to generate a random
sequence of permutations, which was used to produce a list of
patient randomisation numbers. The numbers were then allocated
to each centre and strata in equal frequencies for each treatment
arm.
Treatment
All patients were scheduled to receive concomitant chemo-
radiotherapy followed by chemotherapy alone. The first fraction
of radiotherapy and the first cycle of chemotherapy began on the
same day.
Radiation The radiation dose regimen was the same in both
arms. Megavoltage 46MV was used with 3–4 beams and a total
dose of 50Gy at the intersection of all fields and to lymph nodes if
any; 2Gy per fraction, five fractions per week were delivered. All
fields were used every day and the maximum dose to the spinal
cord was 40Gy. Computerised imaging was used to define the
target volumes.
The target volume included the primary tumour, that is, the
gross tumour volume, distal and proximal margins of 3–5cm and
lateral margins of 2cm at mediastinal interface (PTV). The
accepted PTV coverage had to respect the constraints of the ICRU
report, between 95 and 107% of the prescribed dose. For upper
third primaries, the subclavicular lymph nodes were included. For
middle third tumours, the right and left retro-clavicular regions
were included in the initial target volume when the upper limit of
the tumour exceeded the carena. For lower third cancers, the
irradiated field included the coeliac lymph nodes. The choice of
technique (number and orientation of the beams) resulted from
the analysis of the lung dose–volume histogram and CTV.
Whenever possible, the following constraints were respected: lung
dose (volume of the two lungs – PTV) receiving 420Gy (V20)
o20% of the total lung volume. Control portal images were to be
performed for each field at the start and at each ballistic change.
Chemotherapy Patients randomised to arm A received, every
2 weeks, six cycles of FOLFOX4, the three first cycles concomitant
with radiotherapy. The FOLFOX4 regimen (doses in mgm
 2) was
oxaliplatin 85 on day 1 and leucovorin 200, both as a 2-h intra-
venous infusion then bolus fluorouracil 400 followed by fluoro-
uracil 600 in 22-h infusions on days 1 and 2. Treatment with
FOLFOX4 continued after the end of radiotherapy for three cycles
(Figure 1). Patients randomised to arm B received two cycles
of cisplatin/fluorouracil on weeks 1 and 5 during radiotherapy
and two other cycles after the end of radiotherapy on weeks 8
and 11. The chemotherapy regimen included cisplatin 75mgm
 2
on day 1 with standard hydration followed by fluorouracil
1000mgm
 2day
 1 i.v. by continuous infusion from day 1 to
day 4 of each cycle (Al-Sarraf et al, 1997; Cooper et al, 1999).
Both chemotherapy regimens were stopped in case of disease
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Figure 1 Treatment schedules. (A) Cisplatin/fluorouracil: four cycles of 4 days. (B) FOLFOX4: six cycles of 2 days.
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tions and delays for chemotherapy and interruptions for radio-
therapy were planned according to toxicities. If interruption of
either radiotherapy or chemotherapy lasted 42 weeks, the patient
was considered off study and was followed for safety. Appropriate
antiemetics were prescribed. Hematopoietic growth factors and
oesophageal dilatation were not permitted during treatment.
Pretreatment evaluation and assessments
All patients underwent a complete history and physical exami-
nation, ECG, biological and CBC before entry, then weekly CBC
and every 2 weeks, physical examination and safety evaluation
of the treatment along with biochemistry. Tumour assessments
were performed with CT scan, barium swallow, oesophagoscopy
and biopsies, bronchoscopy, and endoscopic ultrasonography
(EUS) when feasible. Tumours with tight malignant oesophageal
strictures that preclude passage of the echoendoscope were
considered at least T3 stage and were evaluated with CT scan. In
both arms, tumour evaluations were repeated at week 15 and
every 6 months in complete responders until disease progression.
If the response was considered as partial at the first assessment
or in case of any doubt on endoscopic response (ulceration or
stenosis), a second evaluation with CT scan, endoscopic examina-
tion and biopsies were to be performed within 2 months.
Evaluations
Full treatment Patients were considered as having completed the
treatment if they had received six cycles of FOLFOX4 or four cycles
of cisplatin/fluorouracil.
Tumour response Patients had to have received 50Gy and a
minimum of three cycles of FOLFOX4 or two cycles of the cisplatin/
fluorouracil to be considered evaluable for response. Tumour
responses were assessed during week 15 according to Response
Evaluation Criteria in Solid Tumours (RECIST) Guidelines (Therasse
et al, 2000). The primary tumour was assessed on CT scan with
measure of the vertical length and maximal thickness of the
oesophageal wall on transverse plane. Endoscopic complete response
(CR) was defined as the complete disappearance of any tumour,
ulceration or stenosis with no new lesion (all endoscopic pictures and
reports had to be available), observation of the entire oesophagus as
defined by Tahara et al (2005), but also no CT-scan progression.
Biopsies were not mandatory. Assessment of endoscopic CR was
performed by the IDMC on the population evaluable for response,
that is, those who received concomitant chemoradiotherapy. An
intent-to-treat analysis (on all randomised patients) was planned for
a l lo t h e re n dp o i n t s .P r o g r e s s i o n - f r e es u r v i v a l( P F S )w a sd e f i n e da s
the date from randomisation to tumour progression or death. Overall
survival was measured from date of study entry to date of death.
Toxicity All patients who had received at least one dose of
chemotherapy and/or one fraction of radiotherapy were consi-
dered evaluable for safety. Toxicities were recorded according to
the NCI-CTC version 3 (http://ctep.cancer.gov/protocoldevelopment/
electronic_applications/docs/ctcaev3.pdf).
Statistical analysis
Determination of sample size A sample size of 40 patients in each
arm was designed to achieve at least 85% power, to observe 40%
endoscopic CR, and to exclude a lower limit of confidence interval
(CI) of 20% CR. A 10% adjustment for drop-outs resulted in a
sample size of 88 patients. A two-sided, binomial hypothesis test
with a target significance level of 0.05 was used.
Descriptive statistics The per-protocol population corresponds
to all eligible patients in whom endoscopic response may be
evaluated. The Kaplan–Meier method was used to estimate
Randomised
N = 97
Treatment arm A
(FOLFOX4 regimen)
N = 53
Treatment arm B
(Cisplatin/fluorouracil
regimen) N=44
ITT population          N = 53
Safety population         N = 52
Ineligible           N = 2
Eligible population         N = 51
Tumour response evaluable population   N = 47
ITT population          N = 44
Safety population         N = 43
Ineligible           N = 1
Eligible population         N = 43
Tumour response evaluable population   N = 40
Completed the
study treatment
N = 37
Prematurely discontinued the
study treatment
N = 13
Prematurely discontinued
the study treatment
N = 16
Completed the
study treatment
N = 31
Reasons for discontinuation
AE         7
Disease progression     1
Voluntary withdrawal     1
Death         5
Other*         2
Reasons for discontinuation
AE       6
Death       4
Other**       3
Figure 2 CONSORT diagram. *One patient had hepatic and pulmonary metastases and one patient had oesophageal prothesis. **One patient had
ischaemia on myocardial scintigraphy, one patient was not compliant and one patient did not start chemotherapy because of one SAE.
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ssurvival rates. Hazard ratios and 95% CIs were estimated from Cox
proportional hazards models adjusted for the stratification factor
used in the randomisation. Analyses were generated using SAS
version 8.2 or higher (SAS Institute, Cary, NC, USA).
RESULTS
From October 2004 to December 2005, 97 patients were
randomised in 21 centres (Figure 2): 53 patients were included
in the FOLFOX4 regimen (arm A) and 44 patients in the cisplatin/
fluorouracil regimen (arm B). Two ineligible patients (one in each
arm) did not receive any treatment (one metastatic, one
myocardial ischaemia before treatment). Another patient in arm
A was considered ineligible (in situ carcinoma), but was included
in the safety population for response. A total of 95 patients (97.9%)
were included in the safety population (arm A/B, 52/43). Four
other patients in arm A and three patients in arm B were not
evaluable for tumour response due to oesophageal prothesis, no
chemotherapy or incomplete chemotherapy and/or dose of radio-
therapy o45Gy.
Patient characteristics
Both arms were similar for demographic and baseline chara-
cteristics, although slightly more patients had a baseline ECOG PS
of 0 in arm A (67.9%) as compared with arm B (54.5%). The
majority of patients had squamous cell carcinoma and stage III
disease located in the middle thoracic oesophagus (Table 1). One
third of patients (35/97, 36%) had cervical or upper third thoracic
tumours. The proportion of cT3 tumours was similar in both arms
(arms A/B: 79.2%/81.2%).
Completion of treatment
A total of 68 patients (70.1%) completed the treatment. Premature
discontinuation of treatment was due to adverse events
(AEs; 13.2%/13.6% in arms A/B) or death (9.4%/9.1%, in arms
A/B; Figure 2). In the ITT population, 37 patients (69.8%) in arm A
and 31 patients (70.4%) in arm B completed the full treatment,
including all cycles of chemotherapy. In arm A, dose reductions
were observed in 13 out of 52 patients (25%) for oxaliplatin and in
19 out of 52 patients (36.5%) for fluorouracil. In arm B, 9 out of 43
patients (20.9%) had cisplatin dose reduction and 14 out of 43
(32.6%) had fluorouracil dose reduction. The majority of dose
reductions were due to neutropenia or thrombocytopenia. Almost
all patients (497%) in both treatment arms completed the 5 weeks
of radiotherapy. The median radiotherapy dose received was 50Gy
(range: 28–50) in arm A and 50Gy (range: 14–50) in arm B. Six
patients (11.5%) in arm A and three patients (7%) in arm B had an
AE leading to temporary discontinuation of radiotherapy.
Response
According to the IDMC, an endoscopic CR was reported in 21 out
of 47 patients (44.7%; 95% CI: 30.2%, 59.9%) in arm A and in 12
out of 40 patients (30%; 95% CI: 15.8%, 44.2%) in arm B (Table 2).
According to the investigators, CR was observed in 20 patients
(42.6%; 95% CI: 28.2%, 57.8%) in arm A and 18 patients (43.9%;
95% CI: 28.5%, 60.3%) in arm B. Reasons for discrepancies
between investigator assessments and IDMC (CR downgraded to
no CR) were persistence of an oesophageal ulceration (six patients)
and persistent impassable stenosis (three patients). Two patients
Table 1 Baseline characteristics (ITT population)
Arm A FOLFOX4
(N¼53)
Arm B cisplatin/
fluorouracil (N¼44)
Gender (n (%))
Male 45 (84.9%) 38 (86.4%)
Age (years)
Median 59.0 58.0
Range 39–81 41–80
ECOG PS at baseline (n (%))
0 36 (67.9%) 24 (54.5%)
1 17 (32.1%) 18 (40.9%)
2 0 2 (4.5%)
Histological type (n (%))
Adenocarcinoma 11 (20.8%) 6 (13.6%)
Squamous cell carcinoma 42 (79.2%) 38 (86.4%)
TNM classification (n (%))
Stage IIA 13 (24.5%) 15 (34.1%)
Stage IIB 6 (11.3%) 2 (4.5%)
Stage III 30 (56.6%) 24 (54.5%)
Stage IVA 4 (7.5%) 3 (6.8%)
Location of primary tumour (n (%))
Cervical 6 (11.3%) 1 (2.3%)
Upper thoracic 14 (26.4%) 14 (31.8%)
Middle thoracic 21 (39.6%) 22 (50.0%)
Lower thoracic 14 (26.4%) 9 (20.5%)
Inoperability (n (%))
Carcinologic reason 31 (58.5%) 25 (26.8%)
Therapeutic/patient choice 18 (34.0%) 12 (27.3%)
Weight loss
o10% 32/52 (61.6%) 26/43 (60.5%)
X10% 20/52 (37.4%) 16/43 (37.2%)
Median tumour
length (mm) (range)
50 (15–200)
a 50 (23–130)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; FOLFOX¼
oxaliplatin, fluorouracil and leucovorin; ITT¼intent to treat; PS¼performance
status.
aUnavailable for one patient.
Table 2 Tumour response
FOLFOX
arm A (N¼47)
5FU-cisplatin
arm B (N¼40)
n (%)
(95% CI)
(exact) n (%)
(95% CI)
(exact)
Complete endoscopic response rate assessed by the IDMC
CR 21 (44.7) (30.2–59.9) 12 (30) (15.8–44.2)
Squamous cell 17 (40.5) (25.6–55.3) 10 (26.3) (12.3–40.3)
Adenocarcinoma 4 (36.4) (10.9–69.2) 2 (33.3) (4.3–77.7)
No CR 18 (38.3) (24.5–53.6) 21 (51.2) (35.1–67.1)
Not evaluable 2 (4.3) (0.5–14.5) 4 (10) (0.7–19.3)
Not assessed 6 (12.8) — 5 (12.2) —
Overall response rate assessed by the investigator (Tumour response evaluable
population)–RECIST criteria
CR 20 (42.6) (28.3–57.8) 18 (43.9) (28.5–60.3)
PR 17 (36.2) (22.7–51.5) 10 (24.4) (12.4–40.3)
ORR (CR+PR) 37 (78.7) (64.3–89.3) 28 (68.3) (51.9–81.9)
SD 2 (4.3) (0.5–14.5) 4 (9.8) (2.7–23.1)
PD 4 (8.5) (2.4–20.4) 4 (9.8) (2.7–23.1)
Not evaluable 0 (0.0–7.5) 1 (2.4) (0.1–12.9)
Not assessed 4 (8.5) — 3 (7.3) —
Missing 0 — 1 (2.4) —
Abbreviations: CI¼confidence interval; CR¼complete response; FOLFOX¼
oxaliplatin, fluorouracil and leucovorin; IDMC¼independent data monitoring
committee; ORR¼objective response rate; PD¼progressive disease;
RECIST¼Response Evaluation Criteria in Solid Tumours; SD¼stable disease.
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considered as nonevaluable for response (according to the
protocol) by the IDMC because only one or two cycles of chemo-
therapy were administered. One patient in the FOLFOX arm
claimed as CR by the investigator was considered as nonevaluable
by the IDMC members because of an oesophageal prosthesis. The
IDMC also reclassified two PR in CR because of a further normal
endoscopy with negative biopsies and normal CT scan.
Survival
The median follow-up was 15 months. Median survival time was
22.7 months (95% CI: 16.1% -not reached) in arm A and 15.1
months (95% CI: 9.6%, 19.0%) in arm B. At 1 year, the survival rate
was 75% in arm A and 58% in arm B. At 3 years, the survival rates
were 45% (95% CI: 28%, 63%) in arm A and 29% (95% CI: 13%,
46%) in arm B (Figure 3).
PFS
The median PFS was 15.2 months (95% CI: 10.4%, 21.7%) in arm A
and 9.2 months (95% CI: 6.9%, 14.5%) in arm B.
Safety
The most frequently reported AEs (all grades) were nausea and
neutropenia. Treatment-related paresthesias occurred in 24
patients (46.2%) in arm A and 2 patients (4.7%) in arm B.
A total of 31 patients (59.6%) in arm A and 27 patients (62.8%)
in arm B had grade 3 or 4 related AE (Table 3). The most
frequently reported grade 3–4 related AEs were neutropenia and
dysphagia. No grade 3–4 diarrhoea occurred. A total of 32 patients
(61.5%) in arm A and 24 patients (55.8%) in arm B reported
serious AE (SAE). The most frequently reported SAEs were
dysphagia and febrile neutropenia.
Five deaths were considered possibly related to the study
treatment: one in arm A (pneumopathy and denutrition in a
context of progressive disease), and four in arm B (pancytopenia,
pulmonary infection/grade 4 neutropenia/dehydration/stroke,
cardiac ischaemia, infection/neutropenia). All were male and had
squamous cell carcinoma and no obvious risk factor except ECOG
PS 2 in one patient and age over 70 in another patient.
DISCUSSION
This FOLFOX4–radiation combination achieved an endo-
scopic CR in 44.7% of patients with acceptable toxicity and one
possibly treatment-related death. The control arm with cisplatin–
fluorouracil did apparently worse as endoscopic CR was observed
in only 29.3% of patients and four toxic deaths were noted.
The endoscopic CR was chosen as the primary end point for the
phase II part of this study for convenience and because it was
demonstrated to be a good surrogate end point for overall survival
(Brown et al, 2004; Kalha et al, 2004). The other reason was that
CT scan and EUS are notoriously unreliable in the restaging
after chemoradiation (Kalha et al, 2004; Westerterp et al, 2005).
Persistence of a residual thickening of the oesophageal wall on
CT scan is not incompatible with the subsequent finding
of a histological CR as demonstrated in neoadjuvant studies
(Westerterp et al, 2005). This low accuracy of imaging techniques
is related to the difficulty in differentiating viable tumour from
inflammatory changes or scar tissue (Kalha et al, 2004; Westerterp
et al, 2005). FDG-PET scan showed some promises for restaging
tumours, but it was not widely available at the time this study was
designed.
RECIST guidelines do not refer to endoscopy CR criteria in
much detail (Therasse et al, 2000). No studies on chemoradio-
therapy for localised EC have precisely defined CR criteria for the
primary tumour as outlined by Tahara et al (2005). In our study,
endoscopic CR was precisely defined upon endoscopic observation
of the entire oesophagus as disappearance of the tumour lesion, no
ulceration, no budding, no new lesion on endoscopy and no local
progression on CT scan. Rebiopsy after chemoradiation was not
mandatory in this trial because at the time it was designed, several
studies, performed in the neoadjuvant setting, have shown a high
false negative rate of biopsies in this setting (Poplin et al, 1987;
Vogel et al, 1995; Adelstein et al, 1997; Bedenne et al, 1998;
Triboulet et al, 1998). Endoscopic biopsy samples of superficial
mucosa cannot identify residual tumour deeper within the
oesophageal wall and limits its effectiveness. This has been
subsequently confirmed in larger series (Schneider et al, 2008;
Sarkaria et al, 2009).
The present study also showed that chemoradiotherapy with
FOLFOX4 and 50Gy is feasible in EC as B70% of patients
completed the full treatment in the both arms. Acute toxicity was
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Figure 3 Overall survival (ITT population).
Table 3 Grade 3–4 adverse events
FOLFOX4
(N¼52)
5FU-cisplatin
(N¼43)
n (%) n (%)
Number of patients with any
grade 3 or 4 adverse events
39 (75.0) 31 (72.1)
Haematological 39 (75.0) 31 (72.1)
Neutropenia 12 (23.1) 9 (20.9)
Thrombocytopenia 5 (9.6) 5 (11.6)
Febrile neutropenia 5 (9.6) 2 (4.7)
Anaemia 2 (3.8) 3 (7.0)
Leucopenia 3 (5.8) 1 (2.3)
Febrile bone marrow aplasia 1 (1.9) 1 (2.3)
Pancytopenia 1 (1.9) 1 (2.3)
Dysphagia 10 (19.2) 7 (16.3)
Radiation-related oesophagitis 4 (5.8) 6 (14.0)
Stomatitis 3 (5.8) 0
Odynophagia 1 (1.9) 2 (4.7)
Oesophageal pain 1 (1.9) 1 (2.3)
Asthenia 4 (7.7) 4 (9.3)
Mucosal inflammation 4 (7.7) 1 (2.3)
Fatigue 2 (3.8) 2 (4.7)
Chest pain 0 2 (4.7)
Neutropenic infection 2 (3.8) 2 (4.7)
Weight decreased 2 (3.8) 2 (4.7)
Anorexia 2 (3.8) 2 (4.7)
Hypocalcaemia 0 2 (4.7)
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one related death compared with four deaths in the control arm.
As compared with cisplatin, the administration of oxaliplatin
is convenient and does not require planned hydration and
considerably shortens the duration of outpatient visits. Other
groups showed that different oxaliplatin-based regimens with
concomitant radiotherapy provide promising activity with good
tolerance (Khushalani et al, 2002; O’Connor et al, 2007; Leichman
et al, 2009).
Median survival in the cisplatin–fluorouracil group was 15.1
months and is comparable to those obtain in the RTOG 85-01
study (14.1 months) and in the RTOG 94-05 trial (18.1 months
in the 50.4Gy arm; Al-Sarraf et al, 1997; Cooper et al, 1999;
Minsky et al, 2002). In the FOLFOX4 group, the median survival
was 22.7 months. Noteworthy, this rather good median survival
was obtained while M1a staged patients were allowed to enter the
study, contrary to the RTOG 94-05 study. This difference of 6–7
months in median PFS and survival in our trial appears promising.
This study has obvious limitations, including the imbalanced
number of patients between both arms. Although no randomisa-
tion errors were identified during the study, more patients
were randomised in arm A than in arm B. Actually, 21 active
centres started at least one randomisation block and some of
them were not attributed in totality to patients and, by chance,
more allocations to the experimental arm were made in these
noncompleted blocks. Few patients were ineligible, but comparable
numbers of patients were evaluable for response and safety.
Both groups of patients were well balanced for the main survival
prognostic factors, which were relevant at the onset of the trial,
that is, stage, tumour length o50mm and weight loss o10% (Coia
et al, 2000; Thomas et al, 2004; Di Fiore et al, 2007). In other series,
ECOG PS score 1 or 2 and adenocarcinoma type were identified as
independent predictive factors of poor outcome (Gill et al, 1992;
Cooper et al, 1999).
CONCLUSION
Combination of FOLFOX4 and 50Gy radiation showed a good
efficacy/safety balance and achieved promising results. As the
preplanned objectives of our study were fulfilled, a phase III study
comparing the same regimens was started with PFS as primary end
point.
This on-going study with other trials testing FOLFOX will define
the place of the chemoradiotherapy with FOLFOX in the
armamentarium of EC treatments.
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